BUZZ-Pacira BioSciences stock surges on Viatris' $1.65 billion acquisition deal
路透社2026/10/08 12:31On October 8, Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30 as Viatris (VTRS.O) announced it will acquire Pacira BioSciences for $1.65 billion in cash, at a price of $36.50 per share. This offer represents a premium of approximately 44.8% over Pacira's last closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris’ product portfolio. Both parties expect the deal to be completed by the end of 2026. As of the previous trading day’s close, PCRX was down 2.6% year-to-date.
October 8 - ** Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30
** Viatris VTRS.O will acquire Pacira BioSciences for $1.65 billion (link) in cash, at a price of $36.50 per share
** The offer represents a premium of approximately 44.8% over Pacira’s last closing price of $25.20
** This deal will add Pacira's non-opioid pain medicines Exparel and Zilretta to Viatris's portfolio
** Both parties expect to complete the transaction by the end of 2026
** As of the previous trading day close, PCRX has fallen 2.6% year to date
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or miss required contexts, Reuters does not guarantee the accuracy of the translated text and provides it for reader convenience only. Reuters assumes no responsibility for any damage or loss resulting from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000
PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.
Altcoin Rises 138% in One Month and Enters Top 20, What’s Behind the Rally? Here Are the Details
OpenAI's annualized revenue aims for $70 billions, with enterprise business as a driving force
According to sources familiar with the matter, OpenAI is expected to reach or exceed an annualized revenue of 7 billion dollars by the end of this year, mainly driven by the growth of its enterprise business.
October 9 Crypto News and Market Trends | BTC/ETH/SOL Resistance & Support
Crypto prices
More
